Social Media Ideas for Fda And Pharma

<![CDATA[The Industry’s Communication and Engagement with FDA]]>

<![CDATA[How Pharma is Adjusting Strategies for Changing Dynamics at FDA]]>

<![CDATA[The Evolving Relationship Between FDA and Biotech]]>

<![CDATA[What Does the Regulatory Landscape Look Like From the Other Side of FDA?]]>

FDA halts release of new drug rejection letters while working to formalize policy

The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has learned, following a citizen’s petition from an unna...

<![CDATA[FDA's Timeline for DTC Prescription Drug Ad Oversight]]>

<![CDATA[FDA Pauses Release of New CRL’s Following Citizen’s Petition ]]>

<![CDATA[FDA’s New Pilot Program and Real-Time Review of Clinical Data]]>

<![CDATA[How Do You Think Ai Can Improve FDA's Internal Process?]]>

<![CDATA[The Risks and Benefits of FDA Reviewing Real-Time Data]]>

<![CDATA[FDA Pilot Targets Faster Early-Stage Drug Trial Starts]]>

<![CDATA[U.S. Supreme Court Weighs Inducement Liability Beyond FDA Carve-Out Labels]]>

<![CDATA[What Pharma Investors Should Expect in the Current Regulatory Environment]]>

<![CDATA[FDA Sends CRL to Cingulate for CTx-1301]]>

<![CDATA[Does FDA's Shift From Two Pivotal Trials to One Represent a Genuine Evolution?]]>

<![CDATA[The Push at FDA to Tighten Oversight on DTC Prescription Drug Ads]]>

At the Half: No Free Kicks in FDA’s 2026 Enforcement

As the World Cup has captured the attention of viewers around the globe, so has the Food and Drug Administration (FDA) when it comes to taking enforcement action against regulated...

<![CDATA[FDA Issues CRL to Elevar Therpaeutics for Combination of Rivoceranib and Camrelizumab ]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Utebzi and Capvaxive]]>

FDA discloses why drugs don’t make it to market. A pharma company says it’s bad for business

Last year, the FDA started telling the public why it rejects new drugs. Now a pharmaceutical company says that transparency is bad for business — and wants the agency to reconsider...

<![CDATA[FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010 ]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Issues CRL to Elevar Therapeutics]]>

<![CDATA[How Leadership Changes at FDA Impact its Strategy on DTC Drug Advertisements]]>

<![CDATA[Pharma at a Political Crossroads]]>